What Sphaira does

Sphaira Inc. is a privately held Physical AI company developing autonomous transport systems for the built environment, with its legal headquarters in Cambridge, Massachusetts and operational roots in Berlin, Germany. Its core product, Moby (the Mobile Protective Bubble System), is an autonomous platform designed to move patients within hospitals without continuous human intervention, and the company has coined the term 'intramobility' to describe automated human transport inside facilities as a new mobility category. Moby has been in continuous operational use at Charité - Universitätsmedizin Berlin for approximately 1.5 years and is currently undergoing FDA approval, with parallel clinical studies being run at Stanford Children's Hospital and a development agreement in place with Mayo Clinic.

The company's underlying technology stack combines autonomous navigation, perception, and protective enclosure engineering targeted specifically at intra-facility patient transport, rather than outdoor autonomous vehicles. Sphaira monetizes via enterprise hardware sales and likely associated services to large hospital systems, with reference customers in tertiary care (Charité, Mayo Clinic, Stanford Children's, University Hospital Schleswig-Holstein). Go-to-market is partnership-driven and regulatory-gated: the company relies on development agreements, pilots, and clinical studies with marquee healthcare institutions to build validation, and is pursuing FDA clearance as the gating milestone for US commercialization. Airports are identified as a secondary long-term vertical. Capital backing to date consists of a $2.2M investment from Investitionsbank Berlin in September 2022 and program support from Endless Frontier Labs and NVIDIA Inception.

Operationally, Sphaira is a very early-stage company with 1-10 disclosed employees, no public revenue, and a single deployed product in limited use. The investment-relevant evidence base is thin: there are no disclosed headcount growth trends, no published patents, no named management team beyond founder/CEO Janis Münch, and no cap-table detail. The strategic trajectory hinges on FDA clearance for Moby and conversion of clinical-study and development-agreement relationships at Mayo Clinic and Stanford into paid deployments, with the Charité Berlin site continuing to function as the primary operational reference.

Name

Sphaira

Legal name

Sphaira Inc.

Website

https://sphaira.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Sphaira Inc. is a Physical AI company building the Moby autonomous mobile protective bubble system for patient transport inside hospitals, with deployment at Charité Berlin and ongoing clinical studies at Mayo Clinic and Stanford Children's Hospital ahead of FDA clearance.

Ownership category

akta.pro rank

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Patient Lifts, Transfer & Safe Handling Equipment (Hoists, Slings, Transfer Boards) (HLAHAMAE)

Keywords

• Autonomous patient transport
• Healthcare robotics
• Hospital logistics automation
• Physical AI mobility
• Intramobility technology

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

Revenue model

1. Autonomous Patient Transport Systems: Revenue likely generated through sale or lease of autonomous transport robots and associated software/subscription services to healthcare systems. The technology replaces human transporters, creating operational cost savings that can offset system costs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Sphaira develops and sells the Moby (Mobile Protective Bubble System), an autonomous Physical AI system that transports patients within hospitals without continuous human intervention. The product is designed to replace two to three human patient transporters per unit and is deployed at Charité Berlin (1.5 years operational use), with development agreements at Mayo Clinic and clinical studies at Stanford Children's Hospital, while pursuing FDA approval for US commercialization.

Product overview

Sphaira offers a single core product platform called Moby (Mobile Protective Bubble System) for autonomous patient transport. The product is a Physical AI system that automates human transport within hospitals, designed to work alongside clinical staff to move patients autonomously. The company is currently focused on FDA approval for the Moby system while operating pilot programs with leading healthcare institutions including Charité Berlin, Mayo Clinic, and Stanford Children's Hospital.

Differentiator

Problem solved

Functional benefit

Brands

• Moby: Mobile protective bubble system for autonomous patient transport. Undergoing FDA approval. In clinical use at Charité Berlin and undergoing clinical study at Stanford Children's Hospital.

Quantifiable outcome

• 200-300% efficiency increase in hospital patient transport operations
• +1 more outcomes

Named customers3 records

Segments2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

Three partnerships are on record, tiered core and major.

• Charité BerlincoreStrategic or Co-development PartnerSphaira has an ongoing collaboration with Charité Berlin, Europe's #1 hospital. Their Moby mobile protective bubble system has been in operational use at Charité for 1.5 years. This partnership serves as a primary reference customer and validation site for Sphaira's technology in a real hospital environment.
• Mayo CliniccoreStrategic or Co-development PartnerSphaira announced a development agreement with Mayo Clinic for autonomous patient shuttles. This partnership involves collaborative product development and validation of Sphaira's transport technology in Mayo Clinic's healthcare environment.
• University Hospital Schleswig-HolsteinmajorStrategic or Co-development PartnerSphaira is in collaboration with University Hospital Schleswig-Holstein, a major German university hospital, as part of their healthcare partnership network for product development and validation.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Others

• 6 River Systems (Shopify): 6 River Systems builds autonomous warehouse fulfillment robots; while not a hospital player, its mobile robotics platform and Shopify backing make it a relevant thematic comparable for autonomous-in-built-environments commercialization.
• Panasonic (hospital robotics / HSR): Panasonic has invested in hospital and human-support robots (e.g., HSR platform) and supplies robotics components broadly. It is a thematically adjacent incumbent rather than a direct hospital-transport competitor.

Direct peers

• Diligent Robotics: Diligent Robotics' Moxi robot performs autonomous hospital logistics tasks including supply delivery and patient support. It is the leading US-focused hospital service robot and competes directly with Sphaira for the same hospital automation budget.
• Vecna Robotics: Vecna Robotics builds autonomous mobile robots for material handling in healthcare, warehousing, and manufacturing. Its healthcare logistics robots compete directly with Sphaira for hospital intra-facility transport workloads.
• Relay Robotics (formerly Savioke): Relay Robotics develops autonomous service robots deployed in hospitals and hotels for delivery and patient-facing tasks. Same core technology stack (autonomous indoor mobile robots) and same hospital customer base as Sphaira.
• Aethon (TUG, part of Omnicell): Aethon's TUG autonomous mobile robots perform autonomous delivery and patient/material transport in hospitals, the most direct head-to-head competitor to Sphaira's Moby system. Both target the same clinical logistics use case and same buyer (hospital operations leadership).

Broad incumbents

• Stryker (Mako / hospital equipment): Stryker is a major medical device incumbent with hospital capital equipment relationships and an emerging robotics portfolio. As a broad incumbent, it has the relationships and capital to enter autonomous hospital transport if the category scales.
• Omnicell (parent of Aethon): Omnicell is a large, established healthcare automation vendor that acquired Aethon (TUG) and sells a broad portfolio of hospital pharmacy and supply-chain automation. It is the broad incumbent against which Sphaira must differentiate on patient-specific transport.

Emerging players

• Locus Robotics: Locus Robotics is a leader in autonomous warehouse robots with adjacent technology stack (autonomous mobile manipulation) that could extend into healthcare logistics. Emerging comparable rather than a direct hospital competitor today.
• Mobile Industrial Robots (MiR): MiR manufactures autonomous mobile robots for internal logistics in healthcare, manufacturing, and logistics. Its healthcare-focused deployments are an emerging overlap with Sphaira's hospital transport mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sphaira